Stockscreener 앱 받기
1.32
4.76%
0.06
시장 영업 전:
1.36
0.04
+3.03%
전일 마감가:
$1.26
열려 있는:
$1.23
하루 거래량:
164.14K
Relative Volume:
0.40
시가총액:
$82.85M
수익:
-
순이익/손실:
$-45.08M
주가수익비율:
-1.8082
EPS:
-0.73
순현금흐름:
$-33.68M
1주 성능:
-19.51%
1개월 성능:
-15.92%
6개월 성능:
-51.47%
1년 성능:
-47.41%
1일 변동 폭
$1.23
$1.35
1주일 범위
$1.19
$1.724
52주 변동 폭
$0.726
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
명칭
Galectin Therapeutics Inc
전화
678-620-3186
주소
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
GALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.32 | 82.85M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-13 | 개시 | B. Riley FBR | Buy |
| 2017-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-19 | 개시 | ROTH Capital | Buy |
| 2017-03-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | 다운그레이드 | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-09-21 | 개시 | H.C. Wainwright | Buy |
| 2014-08-01 | 다운그레이드 | Aegis Capital | Buy → Hold |
| 2014-07-30 | 재확인 | MLV & Co | Buy |
| 2014-07-29 | 재확인 | MLV & Co | Buy |
| 2014-04-02 | 재확인 | MLV & Co | Buy |
| 2014-02-10 | 재확인 | Aegis Capital | Buy |
| 2014-01-09 | 재확인 | Aegis Capital | Buy |
| 2013-12-03 | 개시 | MLV & Co | Buy |
| 2013-08-19 | 재확인 | Aegis Capital | Buy |
모두보기
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin Therapeutics (NASDAQ:GALT) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Galectin Therapeutics Reports Promising 2024 Results - TipRanks
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times
Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World
PNC Financial Services Group Inc. Takes $26,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday - Defense World
Best Statistical Liver Cirrhosis Market Growth Set to Surge - openPR.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders - Simply Wall St
Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Yahoo Finance
Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Updates Investors on Clinical Trials - TipRanks
Galectin Therapeutics shareholders elect directors, ratify auditor - MSN
Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. (NASDAQ: GALT) announced significant findings from the NAVIGATE trial regarding belapectin, its therapeutic focus on ta - Defense World
Galectin Therapeutics’ belapectin shows reduction in new varices - TipRanks
Galectin Reports 68% Reduction In New Varices With Belapectin In NAVIGATE Trial U.S. Cohort - Nasdaq
Galectin Therapeutics IncReports Significant Reduction In New Varices With Belapectin - Marketscreener.com
Belapectin shows promise in MASH cirrhosis trial - Investing.com India
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com South Africa
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial - The Manila Times
Major Breakthrough: Galectin's MASH Treatment Cuts Liver Complications by 68% in Latest Trial Data - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Stratos Wealth Partners LTD. - Defense World
Largest borrow rate increases among liquid names - MSN
JPMorgan Chase & Co. Grows Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - The Malaysian Reserve
Liver Cirrhosis Market Forecasted for Strong Growth from 2025 - openPR
Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World
Galectin drops as trial for lead asset fails in MASH - MSN
Galectin Therapeutics shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ: GALT) 8-K Filing Reveals Positive Results from NAVIGATE Trial - Defense World
Barclays PLC Purchases 21,598 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Unveils Promising NAVIGATE Trial Results - TipRanks
HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN
Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World
SouthState Corporation Announces Sale Agreement with Blue Owl Real Estate Capital On January 8, 2025, SouthState Bank, N.A., a subsidiary of SouthState Corporation, has entered into a significant agreement for the purchase and sale of real property w - Defense World
Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat
Liver Cirrhosis Clinical Trial Pipeline Experiences - GlobeNewswire
Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - The Manila Times
Galectin Therapeutics to Present Breakthrough NAVIGATE Trial Results at MASH-TAG 2025 Conference - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Acquires 20,817 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by State Street Corp - Defense World
Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock - Investing.com Nigeria
Galectin Therapeutics Director Increases Stake Amid Strong Momentum, Despite Trial Setbacks - HPBL
Galectin Therapeutics (NASDAQ:GALT) Lowered to “Sell” Rating by StockNews.com - Defense World
Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell" - MarketBeat
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 41.1% in December - MarketBeat
Galectin Therapeutics Inc (GALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):